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The immune response against a viral infection is 
mediated by two different ypes of cells known as B and 
T lymphocytes. The receptor on the B cell is the well- 
characterized antibody molecule, which exists in a 
membrane-bound form and in a secreted form involved 
in the initiation of complement-mediated killing and 
the inactivation of viral particles by direct binding. The 
recognition molecule on T cells is the membrane-bound 
T-cell antigen receptor, which has specificity for a com- 
bination of foreign antigen with a molecule of the 
major histocompatibility complex (MHC), as first dem- 
onstrated by Zinkernagel and Doherty (1974). MHC 
proteins exist in two closely related forms called class I
and class II MHC molecules, both of which are cell- 
surface glycoproteins that are highly polymorphic n the 
human population. In general, class II MHC molecules 
are involved in interactions with T-helper cells, which 
cooperate with B cells to make antibody. Class I MHC 
molecules are recognized by T-killer cells, or cytotoxic 
T lymphocytes, that lyse virally infected cells. In both 
cases, T-cell recognition of antigen together with a 
"self" MHC molecule is termed MHC "restricted" rec- 
ognition (for review, see Davis 1985; Kronenberg et al. 
1986). 
It has now been established that MHC-restricted 
T-cell receptors (TCRs) recognize peptide fragments of 
antigens (presumably derived from intracellular pro- 
cessing) bound to an MHC molecule at what appears to 
be a single site. Two major lines of evidence point to 
the involvement of peptides in T-cell recognition: Pep- 
tide fragments of an antigen added to the outside of 
fixed class II MHC-bearing target cells can be recog- 
nized by T-helper cells specific for the appropriate 
combination of antigen and MHC type (Shimonkevitz 
et al. 1983). Subsequently, short synthetic peptides 
(8-30 residues long) were shown to bind to purified 
class II proteins (Babbitt et al. 1985). In some cases, 
the binding of a particular peptide by an MHC mole- 
cule correlated with the ability of an animal of that 
MHC type to mount an immune response against he 
antigen from which the peptide was derived (Buus et 
al. 1987), suggesting a reason for the observation that 
there is a correlation between immunological response 
to an antigen and certain specificities of histocom- 
patibility molecules (McDevitt et al. 1972). It has been 
much more difficult to demonstrate peptide binding to 
purified class I MHC molecules, although class I and 
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class II MHC molecules are similar in domain organiza- 
tion, sequence, and presumably three-dimensional 
structure (Brown et al. 1988). However, virus-specific 
T-killer cells have been shown to lyse an uninfected 
target cell of appropriate class I specificity to which 
peptide fragments of a viral protein have been added 
(Townsend et al. 1986). By analogy with the work 
described for class II MHC molecules, it is assumed 
that the class I molecules on the target cell bind pep- 
tides, and that it is a peptide/MHC complex that is 
recognized by TCRs on the cytotoxic killer cells. Some 
T cells recognize foreign or "non-self" MHC molecules 
in the apparent absence of antigen, although in these 
cases, it is possible that the peptide-binding site is 
occupied by an endogenous peptide. The reactivity of T 
cells and antibodies against foreign MHC molecules 
leads to host rejection of transplanted tissue. 
The discovery that MHC molecules bind antigenic 
peptides and present hem to T cells has allowed the 
correlation of susceptibility to autoimmune disease 
with certain MHC alleles to be understood on a more 
molecular basis. Any given MHC molecule binds only a 
subset of peptides tested, and as discussed above, the 
ability to bind a peptide can determine the immune 
response to an antigen. Increased susceptibility to au- 
toimmune diseases uch as ankylosying spondylitis and 
insulin-dependent diabetes mellitus are found in in- 
dividuals of certain MHC types, and such diseases arise 
when the body's immune system attacks its own pro- 
teins (for review, see Todd et al. 1988). It is thought 
that the MHC molecules correlated with autoimmune 
disease bind peptides from self proteins, leading to 
tissue damage by self-reactive T-cell clones. 
One hopes that an increased understanding of the 
physical nature of antigenic peptide interactions with 
MHC molecules will allow the design of peptides to 
stimulate the immune response against aviral infection, 
or the design of high-affinity ligands that block the 
self-reactive recognition of MHC molecules involved in 
autoimmune diseases. Before this can be accomplished, 
we will need to understand not only the forces compris- 
ing the peptide/MHC complex, but also how TCRs 
bind to it. In this paper, we briefly discuss what the 
crystal structure of a human class I MHC molecule 
reveals about how histocompatibility molecules might 
interact with TCRs, and we present a hypothetical 
model for how MHC-restricted TCRs bind to the pep- 
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tide/MHC complex. The three-dimensional structure 
of a TCR has not yet been determined, but because of 
the similarity between TCRs and antibodies, we can 
use the known structure of an Fab to serve as a first- 
order TCR model structure, in order to make an edu- 
cated guess about how T-cell recognition of the pep- 
tide/MHC complex occurs. 
TCR Structure and Potential Diversity 
TCRs are membrane-bound disulfide-linked hetero- 
dimers that resemble the Fab fragments of immuno- 
globulins in sequence and domain organization (for 
review, see Kronenberg et al. 1986). Each polypeptide 
chain contains a domain with sequence similarity to 
antibody variable (V) domains, followed by a domain 
similar to an antibody constant (C) domain. Following 
the constant-like domain in each chain, there is a hinge 
region containing a cysteine residue involved in the 
formation of an interchain disulfide bond, and then a 
hydrophobic membrane-spanning sequence and short 
cytoplasmic tail. Figure 1 shows a schematic repre- 
sentation of the primary sequence organization of the 
four TCR polypeptide chains that make up the two 
different ypes of receptor heterodimers (a//3 and 3'/ 
8). As in immunoglobulins, both the a//3 and 3'/8 
TCRs are assembled by the relatively random joining 
of different coding segments to C-region genes (V and J 
join to C in the case of a and 3' chains; V, D, and J join 
to C in the case of/3 and 8 chains). Although variability 
in TCR V regions is less localized than in immuno- 
globulin V regions, hypervariability is found in the 
locations corresponding to the three classic immuno- 
globulin hypervariable regions or complementarity- 
determining regions (CDRs) (Patten et al. 1984; Barth 
et al. 1985), which are known in antibodies to form the 
principal points of contact with antigen (Wu and Kabat 
1970; Kabat et al. 1987). In both antibodies and TCRs, 
the first and second CDR are encoded within the V 
gene segment itself, and the third CDR is formed by 
the junction of the V gene segment with D and J gene 
segments (in the case of immunoglobulin heavy chains 
and TCR/3 and 8 chains) or with J gene segments alone 
(immunoglobulin light chains and TCR a and 3'). 
Although TCRs and immunoglobulins share a similar 
organization of diversity and mechanisms for its gener- 
ation, a closer look at TCR diversity shows a striking 
concentration of sequence polymorphism in the CDR3- 
equivalent region as compared to this region in anti- 
bodies (discussed in more detail in Davis and Bjorkman 
1988). In contrast, TCR diversity within the CDR1- 
and CDR2-equivalent regions is far less pronounced 
than in immunoglobulins. The primary cause of de- 
creased TCR diversity in the first and second CDR 
regions is that there are far fewer TCR V gene seg- 
ments than immunoglobulin V gene segments. Assum- 
ing that the V domains of TCRs pair to form a combin- 
ing site (as is the case for antibody V regions), the 
combinatorial diversity resulting from a random pairing 
of TCR V domains hows even greater disparity from 
the amount of diversity resulting from antibody V re- 
gion pairing. Estimates for the amounts of sequence 
diversity possible for immunoglobulins and TCRs are 
compared in Table 1. As a result of the many mecha- 
nisms generating diversity within the CDR3-equivalent 
or junctional region in TCRs, the potential diversity is 
estimated to be between 4 and 7 orders of magnitude 
higher in TCRs as compared to immunoglobulins. On 
the other hand, the amount of potential TCR nonjunc- 
tional diversity (within the CDR1- and CDR2-equiva- 
lent regions) is estimated to be between 10 and 1000 
times less than that possible for antibodies. 
To rationalize the striking concentration of TCR di- 
versity within the junctional region and relative lack of 
diversity elsewhere, it should be relevant o consider 
what TCRs are known to do, namely, to recognize a
large number of small molecules (i.e., peptides) em- 
bedded in physically larger and much less diverse MHC 
molecules. The simplest interpretation of the skewing 
of diversity in the TCR case toward the CDR3-equiva- 
lent region is that the amino acids in this region are 
mainly interacting with peptide determinants, and that 
residues within the much less diverse CDR1- and 
CDR2-equivalent regions are primarily involved in 
contacts to MHC determinants. 
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Figure 1. Schematic representation of primary 
structure of TCR polypeptides. Leader (L), 
variable (V), diversity (D), and joining (J) gene 
segment contributions are indicated for the vari- 
able domains. The constant portion of each 
TCR polypeptide is divided into the immuno- 
globulin-like constant (C) region, a hinge (H), 
transmembrane (TM) region, and cytoplasmic 
(CY) domain. The approximate locations of cys- 
teine residues involved in disulfide bonds are 
indicated by an external "S" connected to 
another cysteine indicated by an external "S". 
The cysteine in the hinge region is presumed to 
form an interchain disulfide bond. The approxi- 
mate location of CDRI-, CDR2-, and CDR3- 
equivalent regions are indicated by shading in 
the primary structure of the TCR a-chain. 
T-CELL  RECEPTOR/MHC INTERACTIONS 
Table 1. Sequence Diversity in T-cell Receptor and Immunoglobulin Genes 
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Immunoglobulin TCR a//3 TCR 3,/8 
H K a 3 Y $ 
Variable segments 250-1000 250 100 25 7 
Diversity segments 10 0 0 2 0 
Ds read in all frames rarely - -  - -  often - -  
N-region addition V-D, D-J none V-J V-D, D-J V-J 
Joining segments 
Variable region combinations 
Junctional combinations 
4 4 50 12 2 
62,500-250,000 2500 
_1011 - _1015 
10 
2 
often 
V-D1, 
D1-D2, D1-J 
2 
70 
~10 TM 
Calculated potential amino acid sequence diversity in TCR and immunoglobulin genes without allowance for somatic mutation. The 
approximate number of V gene segments are listed for the four TCR polypeptides and contrasted with immunoglobulin heavy and light chains. 
CDR1 and CDR2 are encoded within the V gene segments. The pairing of random V regions generates the combinatorial diversity listed as 
"variable region combinations." Because there are fewer TCR V gene segments han immunoglobulin V gene segments, the combinatorial 
diversity is lower in TCRs than in immunoglobulins. E timates for the number of unique sequences possible within the junctional region are 
contrasted for TCRs and immunoglobulins. Amino acids within CDR3 are encoded almost entirely within the D and/or J region gene segments. 
(The last few amino acids encoded by a TCR V gene segment can contribute o diversity within the TCR CDR3-equivalent region, but the effects 
of these residues on junctional diversity are not included in these calculations.) The mechanisms forgeneration ofdiversity within the junctional 
region that are used for this calculation i clude usage of different D and J gene segments, N region addition up to six nucleotides ateach junction, 
variability in the 3' joining position in V and J gene segments, and translation ofD regions in different reading frames. Numbers are corrected for 
out-of-frame joining codon redundancy and N-region mimicry of germ-line sequences a described by Elliott et al. (1988). 
At  this point, it would be useful to compare the 
three-dimensional structure of a TCR to the structure 
of HLA-A2  to see if there is any structural reason to 
hypothesize the alignment of CDR1 and 2 with MHC 
residues, and CDR3 with residues on a bound peptide. 
Although the crystal structure of a TCR is unknown, 
sequence data suggest hat TCR V regions are folded 
into/3-sandwich structures resembling immunoglobulin 
V regions (Chien et al. 1984; Hedrick et al. 1984; 
Yanagi et al. 1984). In antibodies, the hypervariable or 
CDR regions are located on loops that connect /3- 
strands, and the V regions from the heavy and light 
chains (V H and VL) are paired such that CDR1,2,  and 3 
from each domain are clustered at the ends of the Fab 
arms of the molecule, forming the antigen-binding site 
(for review, see Davies and Metzger 1983). In all of the 
three-dimensional structures of antibodies that are 
known, V H and V L domains have a conserved mode of 
interaction in which they are paired about an approxi- 
mate twofold symmetry axis (i.e., one domain is re- 
lated to the other by a 180 ~ rotation). Thus, in different 
Fabs, the CDR loops are found in the same relative 
positions with respect to each other (Chothia et al. 
1985). A study of immunoglobulin sequences and struc- 
tures has identified conserved amino acids that are 
critical for maintaining the VH-V L contact surface, and 
most of these amino acids are found in homologous 
positions in TCR V region sequences (Novotny et al. 
1986; Chothia et al. 1988). It is therefore likely that 
TCR V domains will not only fold into tertiary struc- 
tures similar to antibody V regions, but that the chain 
pairing and resulting combining sites of TCRs will also 
be similar to those described for antibodies. This con- 
clusion has been recently reached after a systematic 
study of immunoglobulin structures and a comparison 
of TCR and immunoglobulin sequences by Chothia et 
al. (1988). These authors conclude that TCR and anti- 
body V domains will share a similar /3-sheet frame- 
work, as well as a similar domain interface. Strongly 
conserved residues are also found in TCR/3  sequences 
at sites homologous to those that form the conserved 
contact between the framework of the V and C do- 
mains of the immunoglobulin heavy chain, implying 
that V, and C ,  will associate in the same way as V n and 
CH1. We can therefore use what is known about an- 
tigen binding from crystal structures of Fab and of 
Fab/antigen complexes to serve as a guideline for un- 
derstanding how TCRs bind to their ligand. 
In antibodies, the first and second CDRs on V L are 
separate from their counterparts on VH, and the space 
between them is occupied by the CDR3 regions from 
each chain (Davies and Metzger 1983). In Figure 2A, 
the relative locations of the six CDR regions in an 
immunoglobulin combining site are shown (for our 
purposes to represent he approximate structure of a 
TCR combining site). In this view of the VH-V L pair, 
the pseudo twofold axis is perpendicular to the plane of 
the paper and located between the two CDR3 loops. 
Structural studies of antibodies complexed with protein 
antigens have shown that side chains from all six CDRs 
can contact the antigen, and that the entire antigen/ 
antibody interface is a rather fiat surface with protru- 
sions and depressions in the antibody being com- 
plementary to the antigen surface (Amit et al. 1986; 
Colman et al. 1987; Sheriff et al. 1987). Assuming these 
details are also true for the combining site for a TCR,  
we now turn to a discussion of the structure of the TCR 
ligand, i.e., the pept ide /MHC complex. 
MHC Structure 
The three-dimensional structure of HLA-A2 ,  a 
human class I MHC molecule, has been determined 
(Bjorkman et al. 1987a,b), and it is likely that other 
G 
Figure 2. (See facing page for legend9 
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class I as well as class II MHC molecules (Brown et al. 
1988) will fold into similar tertiary structures. The 
HLA-A2 molecule is composed of two structural 
motifs: The membrane proximal a 3 and 132 micro- 
globtilin domains are folded like immunoglobulin C 
domains, and the membrane-distal a 1 and a 2 domains 
consist of a platform of eight g-strands topped by two 
a-helices. The al and a 2 domains have similar tertiary 
structures, each consisting of four/3-strands and a long 
helical region. As is also the case for immunoglobulin 
and presumably TCR V domains, the a 1 and a 2 do- 
mains are related by an approximate wofold symmetry 
axis when they are paired in the HLA structure. Since 
these are the domains that show most of the poly- 
morphism between different alleles, one would expect 
that the peptide-binding site and TCR recognition re- 
gions would be located on this part of the molecule. 
Several ines of evidence suggest he peptide-binding 
site on MHC molecules is the deep groove that sepa- 
rates the two a-helices on its top surface, and that this 
surface is therefore the part of the MHC molecule that 
the TCR recognizes: (1) The groove is located on the 
top of the molecule, and is thus in a likely position to 
interact with a molecule on the surface of another cell. 
(2) The groove is - 25/~ long and - 10/~ wide and 
deep, dimensions consistent with the expectation that 
MHC molecules bind a processed (i.e., peptide) form 
of an antigen. (3) Many of the residues that form the 
sides and the bottom of the site are highly polymorphic 
or have been identified to be critical for T-cell recogni- 
tion of class I molecules, fitting with the expectation 
that MHC polymorphisms affect the peptide binding 
and T-cell reactivity. (4) The crystal structure of HLA- 
A2 shows that the site appears to be occupied by a 
molecule or mixture of molecules that evidently 
copurified and cocrystallized with HLA-A2. Although 
other interpretations are possible, it seems most likely 
that these molecules represent a heterogeneous mix- 
ture of endogenous peptides perhaps added during syn- 
thesis of HLA. If the peptide-binding site is occupied, 
the top surface of the peptide/MHC complex is rela- 
tively fiat, as can be shown by model-building short 
peptides into the HLA-A2 structure. (In fact, in the 
original electron density maps of HLA-A2, the top 
surface of the molecule appears fairly level because of 
the presence of the unknown occupant[s] in this site.) A 
view of the top surface of HLA-A2 combined with a 
12-residue peptide model-built (as an a-helix) into the 
presumed peptide-binding site is shown in Figure 2B 
(to scale with respect o the V regions combining site, 
Fig. 2A). The HLA-A2 structure is discussed in more 
detail by Bjorkman et al. (1987a,b). 
A Model for TCR Recognition of the 
Peptide/MHC Complex 
When the (hypothetical) TCR combining site is com- 
pared to the top surface of the peptide/MHC complex 
that is its ligand, it is interesting to note that the a-  
helices that make up the sides of the MHC peptide- 
binding site are separated by about he same distance as 
separates the CDR1 and 2 regions of one V domain 
from another (18/~). Thus, the relatively fiat surface of 
a peptide/MHC complex could interact with the com- 
bining site of an immunoglobulin-like TCR such that 
the limited diversity in the CDR1- and CDR2-equiva- 
lent regions on TCR V~ and Va contacts the side chains 
of the MHC a-helices, leaving the centrally located and 
very diverse CDR3-equivalent regions to interact with 
the peptide. Using immunoglobulin V regions as a 
model for a TCR and HLA-A2 with a hypothetical 
peptide as the MHC molecule, this type of interaction 
is shown in Figure 2C. A more extensive discussion of 
this model for TCR recognition of peptide/MHC com- 
Figure 2. Representation f the structures of (A) the immunoglobulin a tigen-binding site, (B) the peptide-binding site of an 
MHC molecule, and (C) the alignment of CDRs in a hypothetical TCR over a peptide/MHC complex. (A) View from the top 
(the direction of antigen) of an immunoglobulin combining site (Fab J539; Suh et al. 1986) with the three CDRs on each chain 
highlighted with van der Waals surfaces (CDRI: yellow, CDR2: blue, CDR3: pink, carbon-a backbone of VH and V L shown in 
red). Similarities between TCRs and immunoglobulins suggest that TCR combining sites will preserve the same general features, 
having CDR1 and CDR2 from one domain separate from their counterparts onthe partner domain and the space between them 
occupied by CDR3 from each domain (see text for details). (B) Top surface of an MHC molecule with the side chains of the amino 
acids located in two helices on either side of the peptide-binding site highlighted in blue. A hypothetical peptide (a 12-mer 
polyvaline) has been model-built into the peptide-binding site as an a-helix (shown in pink). Carbon-a backbone of HLA-A2 
(Bjorkman et al. 1987a,b) is shown in green. Note that the distance between the MHC a-helices i approximately the same as the 
distance the first and second CDRs on one V domain are separated from their counterparts onthe partner V domain (see part A). 
(C) Model for TCR interaction with a peptide/MHC complex. The molecules inthis figure are rotated - 90 ~ with respect to their 
orientation in parts A and B on this figure. The antibody V domains (top of figure) here represent a TCR bound to a 
peptide/MHC complex (bottom of figure). The carbon-a backbone of the V domains (red) is shown with the amino acids within 
CDR1 and CDR2 highlighted with blue van der Waals surfaces, and amino acids within CDR3 highlighted inpink van der Waais 
surfaces. The MHC carbon-a backbone is shown in green with side chains located on the a-helices highlighted in blue. A 
(hypothetical) peptide model built into the binding site as an a-helix is shown in pink. The relatively flat surface of the V region 
combining site is complementary to the peptide/MHC complex; with the first and second CDR from each V domain "fitting" over 
an MHC a-helix, leaving the centrally located CDR3 regions aligned over the peptide (see text for details). (D) Side view of 
model for TCR interacting with an MHC molecule. The V domains and MHC molecule have been rotated to show that there is 
sufficient space on the top surface of the MHC molecule for TCR V regions (here depicted as immunoglobulin V regions) to bind 
in several different registers along the MHC a-helices. The carbon-a backbone of VH and V L (here representing TCR V~ and Va ) 
are shown in red and blue (top of figure). At the bottom of the figure are the four domains of a class I MHC molecule (al: green, 
a2: pink, a3: blue, fl2-microglobulin: red). 
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plexes has been published (Davis and Bjorkman 1988), 
and a similar model has been suggested by Claverie and 
co-workers (Claverie et al. 1989). 
This model for TCR and MHC/peptide interactions 
is consistent with some recent work correlating TCR 
a/fl sequences with known antigen-MHC specificities. 
For example, in some cytochrome-c-specific T- ell 
clones, changes in the junctional region alter the 
specificity for peptide without altering MHC specificity 
(Fink et al. 1986; Winoto et al. 1986). Also, some of 
the TCRs from these clones how a selection for certain 
amino acids within the CDR3-equivalent region, sug- 
gesting that junctional residues are important for pep- 
tide recognition (Hedrick et al. 1988). This idea was 
tested by changing one of the conserved junctional 
residues by site-directed mutagenesis, with the result 
that the mutated TCR displayed a different fine 
specificity for antigen (Engel and Hedrick 1988). 
Even within the confines of our model for TCR 
interaction with peptide/MHC complexes, however, 
one would not always expect a direct correlation of 
TCR junctional residues with specificity for a particular 
peptide, for the simple reason that changes in MHC 
residues could alter the conformation or orientation of 
a bound peptide, thus requiring acompensatory change 
in the TCR residues contacting the peptide. Also, we 
would not expect that the V~ and V~ gene segments 
used by T cells restricted to the same MHC molecule 
would always be the same, because the surface of a 
peptide/MHC complex is large enough to allow a TCR 
(assuming an immunoglobulin-like binding site) to bind 
in different registers along the MHC a-helices. In Fig- 
ure 2D, the V-regions/MHC complex has been rotated 
by 90 ~ so that the MHC a-helices are approximately in 
the plane of the paper to demonstrate that there is 
room on the top surface of the MHC molecule for a 
TCR molecule to bind in several different regions. In 
addition, because antibody (and presumably TCR) V 
regions pair with approximate dyad symmetry and be- 
cause the MHC a 1-a 2 domains are approximately d ad 
symmetric, the interaction of CDR1 and CDR2 res- 
idues with MHC determinants and CDR3 with peptide 
determinants can be accomplished in either of two 
orientations related to each other by 180 ~ . (In other 
words, the interaction depicted in Figure 2C would 
look the same if the V regions dimer were rotated by 
180 ~ about its pseudo-dyad axis, which is vertical in this 
figure). 
It is likely that an exact correlation between TCR 
hypervariable r gion sequences and MHC and peptide 
specificities will never be possible, due to the spatial 
proximity of CDR residues in the combining site. Also, 
it is a bit of an oversimplification to assume that TCR 
interactions with ligand will exclusively involve residues 
in the CDR loops, because crystal structures of Fabs 
complexed to protein antigens have shown that frame- 
work residues adjacent o the CDR loops can contact 
the antigen (Amit et al. 1986; Sheriff et al. 1987). 
However, the structural complementarity between the 
MHC peptide-binding site and the (hypothetical) TCR 
combining site depicted in Figure 2C may provide an 
explanation for the original suggestion by Jerne (1971) 
that T-cell antigen receptors and MHC molecules 
coevolved to have some affinity for each other and 
gives us some idea of what MHC-restricted TCR recog- 
nition means at the molecular level. This model also 
provides a rationale for the decreased number of TCR 
V gene segments as compared to immunoglobulin V 
gene segments, because the variability within the por- 
tion of the protein they encode is primarily predicted to 
interact with a limited number of MHC molecules with- 
in any given individual (on the order of 6 class I and 20 
class II MHC molecules in a heterozygous individual). 
Finally, the model may serve as a useful framework for 
the design of experiments o alter TCR residues and 
test the effect on MHC or peptide recognition. 
Thymic Selection 
In a way that is not fully understood, the T cells that 
leave the thymus have receptors that can recognize 
foreign antigen plus self-MHC, but not self-MHC alone 
(or self-MHC plus a self-peptide) when they are in the 
periphery (for review, see Marrack and Kappler 1987). 
It is difficult to understand how this selection can occur, 
since the huge number of foreign peptides that the TCR 
must recognize are not present in the thymus. The 
selection of receptors is thought to operate on two 
levels: There is a "positive" selection for TCRs that 
recognize antigen in the context of their own MHC, 
and a "negative" selection against self-reactive re- 
ceptors to ensure that individuals are tolerant o their 
own proteins. It has been suggested that all TCRs with 
some affinity for self-MHC are selected, but only 
thymocytes with a low affinity for self are allowed to 
mature because the process of tolerance deletes cells 
with TCRs that have a moderate to high affinity for 
self-MHC (Marrack and Kappler 1987). The TCRs 
with low affinity for self-MHC are assumed to have an 
increased affinity for some combination of self-MHC 
plus foreign peptide that they will encounter in the 
periphery. 
It is difficult to understand, however, how a positive- 
ly selected TCR could bind tightly enough to distin- 
guish residues on a self-MHC molecule from a non-self 
molecule, yet apparently disregard interactions with 
any self-peptides that are present on MHC molecules in 
the thymus during selection. As can be seen by exami- 
nation of the HLA-A2 structure, aTCR binding to the 
top surface of the peptide/MHC complex would, by 
necessity, interact with a bound peptide. In fact, be- 
cause of the physical proximity of side chains contri- 
buted by the MHC molecule and side chains from the 
peptide, almost any shape of molecule recognizing the 
top of the MHC molecule could not help but interact 
with parts of a bound peptide. As a way around the 
dilemma of the absence of foreign peptides during 
positive selection, it has been postulated that the 
foreign peptides to which the TCR responds in the 
periphery resemble self-peptides that are bound to 
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MHC molecules in the thymus. As has been suggested 
by Marrack and Kappler (1987), the MHC molecules 
on the thymus cortical epithelial cells might bind a 
different spectrum of peptides than is found elsewhere 
in the animal. In this scenario, these peptides would not 
be found on bone-marrow-derived c lls, hence the pro- 
cess of tolerance would not delete cells with TCRs 
specific for self-MHC plus a thymic cortical epithelial- 
specific peptide. These cells would then go on to join 
the peripheral T-cell pool, where they would respond 
to foreign peptides that resemble the peptide upon 
which they were selected. A variant of this idea sug- 
gests that spontaneous mutation of self-proteins could 
generate enough variants to self-peptides to allow 
TCRs to be selected to recognize a self-MHC plus a 
mutated self-peptide that resembles a foreign peptide 
to be encountered later in the periphery (Kourilsky and 
Claverie 1989). However, it is hard to imagine that 
enough variability in self-peptides would be generated 
to account for a T-cell response against a universe of 
foreign antigens. 
Another way to reconcile the existence of positive 
selection with the absence of foreign antigens in the 
thymus would be to assume that the MHC molecules in 
the thymic cortical epithelium have empty peptide- 
binding sites, which is not unreasonable from a purely 
structural point of view. Since the residues lining the 
site in HLA-A2 are not exclusively hydrophobic (Bjork- 
man et al. 1987b), one could imagine that the peptide- 
binding site could be filled with water molecules, result- 
ing in an empty MHC molecule with a structure similar 
to that of HLA-A2 (in which the site was found to be 
occupied by an unknown molecule or mixture of mole- 
cules). An empty class II MHC molecule is also a 
structural possibility, since an examination of the class 
II MHC sequences shows that the residues predicted to 
be in the peptide-binding site are also not particularly 
hydrophobic. If TCRs are positively selected by bind- 
ing to MHC molecules with empty peptide-binding 
sites, they could recognize the MHC a-helices using 
residues within their CDR1 and CDR2 loops, leaving 
the selection of residues within the CDR3 junctional 
region to be almost completely unconstrained. Follow- 
ing a selection of TCRs with affinity for self-MHC, 
those TCRs with an affinity for self-MHC plus a self- 
peptide could be eliminated by whatever mechanism 
controls negative selection, leaving a number of TCRs 
capable of recognizing a self-MHC plus foreign peptide 
complex. 
The idea that positive selection occurs on empty 
MHC molecules assumes that at least some MHC mole- 
cules in the thymic cortical epithelium are capable of 
reaching the cell surface without a bound peptide. 
However, recent results from Townsend's laboratory 
suggest that the intracellular assembly and cell-surface 
expression of class I MHC molecules are dependent on 
peptide binding (Townsend et al., this volume). It is 
still possible, though, that some small percentage of 
MHC molecules manage to reach the cell surface of the 
thymic cortical epithelium without a bound peptide. 
TCRs that are positively selected by binding to these 
empty molecules could survive a subsequent egative 
selection step, whereas the majority of TCRs that are 
positively selected on MHC molecules occupied with a 
self-peptide would be eliminated during negative 
selection. 
TCR Recognition of Superantigens 
Recently, several self-antigens in combination with 
murine class II MHC molecules have been shown to 
form ligands that are recognized by virtually all T cells 
whose receptors bear certain V~ elements, without ap- 
parent regard to V~, J~, De, or J~ gene usage (Kappler 
et al. 1987, 1988; McDonald et al. 1988; Pullen et al. 
1988). The best-studied such antigen is encoded within 
the Mls locus, and mice combining particular Mls and 
MHC haplotypes are found to have deleted T cells 
bearing certain V~ TCRs during the establishment of
self-tolerance. Assuming that Mls products are pro- 
cessed and presented as peptides bound to MHC mole- 
cules, one interpretation of the correlation of TCR V~ 
sequences with reactivity to Mls is that specific germ- 
line V~-encoded residues are in direct contact with 
antigen. Since this interpretation is in direct conflict 
with our model for TCR interaction with the peptide/ 
MHC complex, we will discuss an alternative xplana- 
tion for these data originally suggested by Janeway and 
colleagues (Janeway et al. 1989). 
The molecular nature of the Mls product is not 
known, but it has been suggested to be many things, 
including a unique peptide bound to an MHC molecule 
(Kappler et al. 1988). However, the T-cell response to 
Mls differs in several ways from a response to conven- 
tional antigens that are recognized as peptides embed- 
ded in MHC molecules: The response is very strong, 
stimulating about 20% of all T cells, and is not strictly 
MHC restricted (Janeway et al. 1989). Recently, the 
T-cell response to certain bacterial enterotoxins has 
been found to closely resemble the response to Mls, 
both in its strength and in the correlation of certain V~ 
TCR chains with T-cell reactivity, and the Mls product 
and the enterotoxins are now being called "superan- 
tigens" (White et al. 1989). In the case of T-cell recog- 
nition of the bacterial enterotoxins, antigen processing 
(i.e., degradation i to peptides) is not required, and 
furthermore, the intact protein has been shown to bind 
to purified class II MHC molecules (Fraser 1989). It is 
therefore likely that the T-cell response to the superan- 
tigens may represent a special mode of recognition in 
which the intact antigen has some intrinsic affinity for 
TCR V~ subunits. The model proposed by Janeway and 
colleagues (Janeway et al. 1989) suggests that a 
superantigen (the Mls product or an enterotoxin) binds 
as an intact protein to the sides of the class II MHC 
molecule and the V~ TCR subunit, effectively forming a 
bridge between the T cell and antigen-presenting cell. 
The interaction between the TCR and peptide/MHC 
complex is thus undisturbed by the superantigen and 
could be as we have proposed (Davis and Bjorkman 
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1988 and this paper). The MHC peptide-binding site 
could even be occupied by an endogenous peptide, 
since the superantigen is proposed to bind in a region 
distinct from this site. Recent data from the laboratory 
of Mathis and Benoist support the contention that 
superantigens do not interact with MHC molecules like 
conventional peptides, in that mutations within the 
peptide-binding site of a class II molecule that abro- 
gated peptide presentation had no effect on the recog- 
nition of the enterotoxin SEB (Dellabona et al., this 
volume). The idea that superantigens are presented to 
T cells in a fundamentally different way from processed 
peptides bound in the MHC peptide-binding site is 
attractive, because it is difficult to envision how the V~ 
portion of the TCR could exclusively contact a peptide 
bound in the binding site of an MHC molecule as we 
understand the architecture of this site from the crystal 
structure of HLA-A2 (Bjorkman et al. 1987a,b). 
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